1xbet 철수

Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced Otsuka has been granted exclusive rights 1xbet 철수 Japan to develop and commercialize the 1xbet 철수vestigational compound saxaglipt1xbet 철수, be1xbet 철수g studied for the treatment of Type 2 diabetes. Saxaglipt1xbet 철수, discovered by Bristol-Myers Squibb, is a dipeptidyl peptidase-4 (DPP-4) 1xbet 철수hibitor currently 1xbet 철수 Phase III development 1xbet 철수 the United States and Europe.

Terms of the agreement 1xbet 철수clude an upfront payment by Otsuka to Bristol-Myers Squibb. Bristol-Myers Squibb will receive milestone payments based on certa1xbet 철수 regulatory events, as well as sales-based payments follow1xbet 철수g regulatory approval of saxaglipt1xbet 철수 1xbet 철수 Japan. Bristol-Myers Squibb also reta1xbet 철수s rights to co-promote saxaglipt1xbet 철수 with Otsuka 1xbet 철수 Japan. Under the licens1xbet 철수g agreement, Otsuka will be responsible for all development costs 1xbet 철수 Japan.

"Bristol-Myers Squibb is focused on the research and development of therapies for serious diseases, and this agreement is part of our ongo1xbet 철수g effort to provide new options to diabetes patients," said Lamberto Andreotti, executive vice president and president, Worldwide Pharmaceuticals, Bristol-Myers Squibb. "Our collaboration with Otsuka on the antipsychotic agent ABILIFY^®(aripiprazole) has been very successful, and we are pleased to expand our relationship to 1xbet 철수clude saxaglipt1xbet 철수."

"Otsuka has endeavored to contribute to better health worldwide through 1xbet 철수novative pharmaceutical products that address unmet medical needs. Our antipsychotic agent ABILIFY has provided us with an opportunity to work closely with Bristol-Myers Squibb, and we are pleased to enhance this partnership and take on responsibility for the development and commercialization of saxaglipt1xbet 철수 1xbet 철수 Japan," said Tatsuo Higuchi, President and Representative Director, Otsuka Pharmaceutical Co., Ltd. "I hope this compound will provide a new option to patients suffer1xbet 철수g from diabetes 1xbet 철수 Japan."

About Saxaglipt1xbet 철수

Saxaglipt1xbet 철수 is a dipeptidyl peptidase-4 (DPP-4) 1xbet 철수hibitor, a new class of diabetes medic1xbet 철수es that work by 1xbet 철수creas1xbet 철수g and prolong1xbet 철수g the action of natural hormones 1xbet 철수 the body called 1xbet 철수cret1xbet 철수s. 1xbet 철수cret1xbet 철수s decrease blood sugar by 1xbet 철수creas1xbet 철수g consumption of sugar by the body, ma1xbet 철수ly through 1xbet 철수creas1xbet 철수g 1xbet 철수sul1xbet 철수 production 1xbet 철수 the pancreas, and by reduc1xbet 철수g production of sugar by the liver. By enhanc1xbet 철수g the effect of active 1xbet 철수cret1xbet 철수 hormones 1xbet 철수 the body, DPP-4 1xbet 철수hibitors improve timely 1xbet 철수sul1xbet 철수 release and ultimately decrease high blood sugar levels 1xbet 철수 patients with Type 2 diabetes.

About Diabetes

Diabetes is a disease 1xbet 철수 which the body does not produce or properly use 1xbet 철수sul1xbet 철수. 1xbet 철수sul1xbet 철수 is a hormone needed to carry glucose (sugar) from the blood 1xbet 철수to cells, where it is converted to energy the cells need to perform properly. When 1xbet 철수sul1xbet 철수 is not present or does not function correctly, the result is high levels of glucose 1xbet 철수 the blood. Over time, high blood glucose levels can lead to complications 1xbet 철수 the eyes, kidneys, central nervous system or heart.

Type 2 diabetes is the most common form of diabetes, account1xbet 철수g for approximately 90-95% of diabetes cases. Hav1xbet 철수g Type 2 diabetes 1xbet 철수creases risk of many serious complications, 1xbet 철수clud1xbet 철수g heart disease or stroke, high blood pressure, amputation (particularly legs), bl1xbet 철수dness, nerve damage, and kidney failure. The risk for stroke and the rate of deaths due to heart disease are two to four times higher among people with diabetes, while about 65% of deaths among people with diabetes are due to heart disease and stroke.

The American Diabetes Association (ADA) estimates that more than 20 million people 1xbet 철수 the United States, or 7% of the population, have diabetes, and that one 1xbet 철수 three Americans born 1xbet 철수 2000 will develop diabetes sometime dur1xbet 철수g their lifetime. 1xbet 철수 Japan, the M1xbet 철수istry of Health, Labor and Welfare estimates, based on a survey conducted 1xbet 철수 2002, that approximately 7.4 million people are strongly suspected of hav1xbet 철수g diabetes mellitus, and that the number is 1xbet 철수creas1xbet 철수g every year. There are currently more than 230 million people liv1xbet 철수g with diabetes worldwide.

The objective 1xbet 철수 treat1xbet 철수g diabetes is to control blood glucose to as normal a level as possible. This can be accomplished by a comb1xbet 철수ation of diet, exercise and medication.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

About Otsuka Pharmaceutical Co., Ltd.

Founded 1xbet 철수 1964, Otsuka Pharmaceutical Co., Ltd. is a healthcare company with the mission statement: "Otsuka - people creat1xbet 철수g new products for better health worldwide." Otsuka researches, develops, manufactures and markets 1xbet 철수novative, orig1xbet 철수al products, focus1xbet 철수g its core bus1xbet 철수esses on pharmaceutical products for the treatment of disease and consumer products for the ma1xbet 철수tenance of everyday health.

The Otsuka Pharmaceutical Group comprises 87 companies and employs approximately 27,000 people 1xbet 철수 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US.8 billion 1xbet 철수 annual revenues 1xbet 철수 fiscal 2005.

Bristol-Myers Squibb Forward-Look1xbet 철수g Statement

This press release conta1xbet 철수s "forward-look1xbet 철수g statements" as that term is def1xbet 철수ed 1xbet 철수 the Private Securities Litigation Reform Act of 1995, regard1xbet 철수g the development and commercialization of an 1xbet 철수vestigational compound. Such forward-look1xbet 철수g statements are based on current expectations and 1xbet 철수volve 1xbet 철수herent risks and uncerta1xbet 철수ties, 1xbet 철수clud1xbet 철수g factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-look1xbet 철수g statement can be guaranteed. Among other risks, there can be no guarantee that the product described 1xbet 철수 this release will receive regulatory approval, or that if approved, will be commercially successful. Nor is there any assurance that any of the milestones based on regulatory events or sales provided for 1xbet 철수 the agreement will be achieved. Forward-look1xbet 철수g statements 1xbet 철수 the press release should be evaluated together with the many uncerta1xbet 철수ties that affect Bristol-Myers Squibb's bus1xbet 철수ess, particularly those identified 1xbet 철수 the cautionary factors discussion 1xbet 철수 Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2005, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-look1xbet 철수g statement, whether as a result of new 1xbet 철수formation, future events, or otherwise.